GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures
GT BIOPHARMA, INC. (GTBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures of 0 shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures · last filed 2021-05-17
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2021-03-31 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2020-12-31 was -452.10K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2020-09-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2020-06-30 was 480.35K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2020 was 28.26K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2019 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2018 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 month |
|---|---|---|---|---|
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-17 | -452.10K shares derived: sum of 2 quarters · filed 2021-05-17 | -452.10K shares derived: sum of 3 quarters · filed 2021-05-17 | 28.26K shares derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-12-31 | -452.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | -452.10K shares derived: sum of 2 quarters · filed 2021-04-16 | 28.26K shares derived: sum of 3 quarters · filed 2021-04-16 | 28.26K shares 10-K · filed 2021-04-16 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | 480.35K shares derived: sum of 2 quarters · filed 2020-11-13 | 480.35K shares 10-Q · filed 2020-11-13 | |
| 2020-06-30 | 480.35K shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | 480.35K shares 10-Q/A · filed 2020-08-18 | ||
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-15 | |||
| 2019-12-31 | 0.00 shares 10-K · filed 2021-04-16 | |||
| 2018-12-31 | 0.00 shares 10-K · filed 2019-03-29 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-03-29 | |||
| 2016-12-31 | 1.17K shares 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |